Lenvenib 10mg Capsule

About

Lenvatinib is a sophisticated multi-kinase inhibitor that targets several crucial receptor tyrosine kinases (RTKs) involved in tumor growth, angiogenesis, and progression. Its primary targets include vascular endothelial growth factor receptor (VEGFR) 1, 2, and 3, fibroblast growth factor receptor (FGFR) 1, 2, 3, and 4, platelet-derived growth factor receptor alpha (PDGFRα), as well as RET and KIT proto-oncogenes. By simultaneously inhibiting these diverse signaling pathways, lenvatinib effectively disrupts the formation of new blood vessels that supply tumors (angiogenesis), directly inhibits cancer cell proliferation, and interferes with other pro-oncogenic processes. This broad-spectrum inhibition makes it a highly effective targeted therapy for several advanced and refractory cancers, including differentiated thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma, by impeding tumor sustenance and growth.

Uses

• Treatment of differentiated thyroid cancer (DTC) that is refractory to radioactive iodine.
• Treatment of advanced renal cell carcinoma (RCC) in combination with everolimus or as monotherapy.
• First-line treatment of unresectable hepatocellular carcinoma (HCC).
• Treatment of advanced endometrial carcinoma in combination with pembrolizumab.

Directions For Use

Take orally once daily, at the same time each day, with or without food, as prescribed by an oncologist.

Benefits

• Significantly improves progression-free survival in various advanced cancers.
• Effective in radioactive iodine-refractory differentiated thyroid cancer.
• Offers a targeted therapy option for renal cell carcinoma.
• Provides a first-line treatment for unresectable hepatocellular carcinoma.
• Can be used in combination therapies for enhanced efficacy.
• Targets multiple pathways involved in tumor growth and angiogenesis.

Side Effects

• Hypertension (high blood pressure)
• Fatigue
• Diarrhea
• Arthralgia/myalgia (joint/muscle pain)
• Decreased appetite
• Nausea
• Vomiting
• Weight decrease
• Proteinuria (protein in urine)
• Palmar-plantar erythrodysesthesia syndrome (hand-foot syndrome)
• Stomatitis (mouth sores)
• Hypothyroidism

Safety Measures

• Alcohol - Avoid or limit alcohol consumption as it may exacerbate liver toxicity or other side effects.
• Pregnancy - Contraindicated in pregnancy due to potential for severe fetal harm; use effective contraception during and after treatment.
• Breastfeeding - Not recommended during breastfeeding as it is unknown if lenvatinib is excreted in human milk and could harm the infant.
• Liver - Use with caution in patients with hepatic impairment; dose adjustment is often required for moderate to severe dysfunction.
• Kidney - Use with caution in patients with renal impairment; dose adjustment may be necessary for severe dysfunction.
• Lung - Monitor for signs of pulmonary embolism or interstitial lung disease, though rare, as these can be serious.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.